Jasper Therapeutics (JSPR) Director Patrick Crutcher Receives Award

What Happened Patrick J. Crutcher, a non‑employee director of Jasper Therapeutics, was granted a derivative award for 7,500 shares on July 31, 2026. The filing reports the acquisition price/value as $0. The award was granted automatically under the company's Non‑Employee Director Compensation Policy and will vest in full on the first anniversary of the grant, subject to Crutcher's continued service through the vesting date. This was a compensation award (not a sale or exercise).

Key Details

• Transaction date: 2026-07-31; Form 4 filed: 2026-08-04 (timely within filing window).
• Transaction type: Award/Grant (derivative) of 7,500 shares; reported acquisition price $0.00.
• Vesting: 100% vests on the first anniversary of the grant, contingent on continued service (per footnote).
• Shares owned after the transaction: not disclosed in this filing.
• Footnote: Grant made automatically under the Issuer's Non‑Employee Director Compensation Policy.
• Exhibit: Exhibit 24 — Power of Attorney included with the filing.

Context This was a routine director compensation grant (an option/award), not an option exercise or open‑market trade. The award does not require cash outlay at grant and will only become an owned equity interest if/when vested and exercised according to plan terms. Such automatic annual grants to non‑employee directors are common and generally reflect governance compensation, not an explicit buy/sell signal.